Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2026-01-07 @ 6:39 PM
Study NCT ID:
NCT03497767
Status:
COMPLETED
Last Update Posted:
2024-05-31
First Post:
2018-02-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
Sponsor:
Trans Tasman Radiation Oncology Group
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
TROG 17.02
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None